| abstract |
(57) Abstract: Prevention of selected diseases and conditions, delay of progression, AT 1 receptor antagonists in combination with (i) AT 1 receptor antagonist or a diuretic used to treat or pharmaceutically in each case, At least two selected from the group consisting of: (ii) an HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof; and (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof. Relates to the combination of two therapeutic combination components. |